Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-21
2006-11-21
Saeed, Kamal A. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S278000, C546S015000, C548S134000
Reexamination Certificate
active
07138400
ABSTRACT:
Novel sulfamides of formula (I) are disclosed. The compounds exert an inhibitory action on the processing of APP by gamma-secretase, and are therefore useful in the treatment or prevention of Alzheimer's disease.
REFERENCES:
patent: 3406184 (1968-10-01), Raasch
patent: 3715362 (1973-02-01), Dominianni
patent: 5703129 (1997-12-01), Felsenstein et al.
patent: 2005/0119293 (2005-06-01), Collins et al.
patent: 2005/0182109 (2005-08-01), Collins et al.
patent: 2005/0182111 (2005-08-01), Pineiro et al.
patent: 2005/0215602 (2005-09-01), Campbell et al.
patent: WO 98/38156 (1998-09-01), None
Aeberli, P., et al, “Neuropharmacological Investigation of N-Benzylsulfamides,” J. Med. Chem., vol. 10(4), pp. 636-642 (Jul. 1967), at p. 637, Table I (compounds 7 and 11).
Castro, J.L., et al., “Synthesis and Biological Activity of 3-[2-(Dimethylamino) ethyl]-5-[(1,1-dioxo-5-methyl-1,2,5-thiadiazolidin-2-yl)-methyl]-1H-indole and Analogues,” J. Med. Chem., vol. 37(19), pp. 3023-3032 (1994) at p. 3027, Table 1, cmpds 8a-8i.
J. E. Franz, et al.: Journal of Organic Chemistry, vol. 29, No. 10, Oct. 1964, pp. 2922-2927.
S. Itsuno, et al.: Journal of the Chemical Society, Perkin Transactions 1, No. 10, Jul. 15, 1999 pp. 2011-2016.
M. Narisada, et al.: Journal of Medicinal Chemistry, vol. 31, No. 9, Sep. 1988, pp. 1847-1854.
K. B. Sharpless, et al.: Journal of Organic Chemistry, vol. 41, No. 1, Jan. 9, 1976, pp. 176-177.
Y. Yamaguchi, et al.: Xenobiotica, vol. 26, No. 6, Jun. 1996, pp. 613-626.
L. H. Zalkow, et al.: Journal of the American Chemical Society, vo. 86, No. 19, Oct. 5, 1964.
L. H. Zalkow, et al.: Journal of Organic Chemistry, vol. 28, No. 12, Dec. 1963, pp. 3303-3309.
G.M. Rishton, et al.: “Fenchylamine sulphonamide inhibitors of amyloid beta peptide production by the gamma-secretase proteolytic pathway: potential small-molecule therapeutic agents for the treatment of Alzheimer's disease” Journal of Medicinal Chemistry, vol. 43, No. 12, May 23, 2000 pp. 2297-2299.
J. E. Franz, et al.: Journal of Organic Chemistry, vol. 29, No. 10, Oct. 1964, pp. 2922-2927.
R. Huisgen, et al.: Chemische Berichte, vol. 98, No. 12, Dec. 1965, pp. 3992-4013.
S. Itsuno, et al.: Journal of the Chemical Society, Perkin Transactions 1, No. 10, Jul. 15, 1999 pp. 2011-2016.
M. Narisada, et al.: Journal of Medicinal Chemistry, vol. 31, No. 9, Sep. 1988, pp. 1847-1854.
K. B. Sharpless, et al.: Journal of Organic Chemistry, vol. 41, No. 1, Jan. 9, 1976, pp. 176-177.
Y. Yamaguchi, et al.: Xenobiotica, vol. 26, No. 6, Jun. 1996, pp. 613-626.
L. H. Zalkow, et al.: Journal of the American Chemical Society, vo. 86, No. 19, Oct. 5, 1964.
L. H. Zalkow, et al.: Journal of Organic Chemistry, vol. 28, No. 12, Dec. 1963, pp. 3303-3309.
Collins Ian James
Hannam Joanne Claire
Harrison Timothy
Lewis Stephen John
Madin Andrew
Grazier Nyeemah
Merck Sharp & Dohme Limited
Saeed Kamal A.
Todaro John C.
Winokur Melvin
LandOfFree
Sulfamides as gamma-secretase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Sulfamides as gamma-secretase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Sulfamides as gamma-secretase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3639543